Stefan Halbherr
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemother Pharmacol 2024; 94:349-360.
15.06.2024Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
15.06.2024Cancer Chemother Pharmacol 2024; 94:349-360
Mc Laughlin Anna M, Hess Dagmar, Michelet Robin, Colombo Ilaria, Haefliger Simon, Bastian Sara, Rabaglio-Poretti Manuela, Schwitter Michael, Fischer Stefanie, Eckhardt Katrin, Hayoz Stefanie, Kopp Christoph, Klose Marian, Sessa Cristiana, Stathis Anastasios, Halbherr Stefan, Huisinga Wilhelm, Jörger Markus, Kloft Charlotte
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio-Poretti M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin A, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Jörger M. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). Eur J Cancer 2024; 201:113588.
02.02.2024TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
02.02.2024Eur J Cancer 2024; 201:113588
Colombo Ilaria, Koster Kira-Lee, Holer Lisa, Haefliger Simon, Rabaglio-Poretti Manuela, Bastian Sara, Schwitter Michael, Eckhardt Katrin, Hayoz Stefanie, Mc Laughlin Anna M, Kloft Charlotte, Klose Marian, Halbherr Stefan, Baumgartner Christian, Sessa Cristiana, Stathis Anastasios, Hess Dagmar, Jörger Markus